CPSE:NSIS B 수익, 비용 및 수입 (DKK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	17,899	3,024	3,325	2,017
30 Sep 23	17,825	3,209	3,291	2,013
30 Jun 23	17,736	3,425	3,319	2,027
31 Mar 23	17,805	3,628	3,284	2,010
31 Dec 22	17,553	3,676	3,198	1,986
30 Sep 22	16,858	3,418	3,292	1,951
30 Jun 22	16,252	3,108	3,108	1,911
31 Mar 22	15,546	3,093	2,995	1,912
31 Dec 21	14,951	3,146	2,828	1,982
30 Sep 21	14,563	3,175	2,492	1,995
30 Jun 21	14,233	3,044	2,397	2,037
31 Mar 21	14,002	2,895	2,308	2,008
31 Dec 20	14,012	2,825	2,299	1,905
30 Sep 20	14,297	3,093	2,303	1,850
30 Jun 20	14,570	3,020	2,431	1,893
31 Mar 20	14,679	3,273	2,497	1,968
31 Dec 19	14,374	3,154	2,459	1,966
30 Sep 19	14,357	3,069	2,492	1,959
30 Jun 19	14,311	3,238	2,398	1,939
31 Mar 19	14,351	3,116	2,351	1,859
31 Dec 18	14,390	3,226	2,334	1,852
30 Sep 18	14,349	3,183	2,322	1,897
30 Jun 18	14,271	3,194	2,308	1,837
31 Mar 18	14,311	3,154	2,382	1,849
31 Dec 17	14,531	3,119	2,470	1,901
30 Sep 17	14,572	3,131	2,486	1,895
30 Jun 17	14,382	3,063	2,468	1,887
31 Mar 17	14,273	3,077	2,439	1,866
31 Dec 16	14,142	3,050	2,414	1,865
30 Sep 16	13,880	2,936	2,434	1,841
30 Jun 16	14,012	2,929	2,477	1,880
31 Mar 16	14,032	2,861	2,464	1,931
31 Dec 15	14,002	2,823	2,462	1,896
30 Sep 15	13,731	2,734	2,390	1,906
30 Jun 15	13,393	2,630	2,342	1,878
31 Mar 15	13,005	2,539	2,324	1,812
31 Dec 14	12,459	2,526	2,276	1,766
30 Sep 14	12,218	2,484	2,338	1,688
30 Jun 14	11,970	2,413	2,311	1,614
31 Mar 14	11,934	2,379	2,332	1,577
31 Dec 13	11,746	2,200	2,321	1,528
30 Sep 13	11,617	2,132	2,253	1,533

양질의 수익: NSIS B 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: NSIS B 의 현재 순이익 이익률 (16.9%) 작년보다 낮습니다 (20.9%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NSIS B 의 수입은 지난 5년 동안 매년 1.5% 씩 증가했습니다.

성장 가속화: NSIS B 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: NSIS B 은 지난 1년 동안 마이너스 수익 성장( -17.7% )을 기록하여 Chemicals 업계 평균( -17.7% ).

자기자본 수익률

높은 ROE: NSIS B 의 자본 수익률( 21.2% )은 높음으로 간주됩니다.

Novozymes 과거 수익 실적

과거 기준 확인 3/6

주요 정보

최근 과거 실적 업데이트

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: Revenues in line with analyst expectations

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent